Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.

Antiviral research - 1 Jan 2022

Leumi Steve, Guo Mingzhe, Lu Jie, Wang Zhaoning, Gan Tianyu, Han Lin, Ngari Jackline, Tong Yimin, Xiang Xiaogang, Xie Qing, Wang Lanfeng, Zhong Jin

Abstract excerpt

Despite the excellent antiviral potency of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), emergence of drug-resistant viral mutations remains a potential challenge. Sofobuvir (SOF), a nucleotide analog targeting HCV NS5B - RNA-dependent RNA polymerase (RdRp), constitutes a key component of many anti-HCV cocktail regimens and confers a high barrier for developing drug resistance. The serine to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Replicon

Share to Sofosbuvir

Source

Identifiers

PMID: 34864126
DOI: 10.1016/j.antiviral.2021.105224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.PMID 34864126Read ↗

Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.Semantic proximity Read ↗

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.Semantic proximity Read ↗

Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.Semantic proximity Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.Semantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirSemantic proximity Read ↗

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Hepatitis C virus genotype 4: A poorly characterized endemic genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.